Anna Dolnik

Anna Dolnik

Auto-generated profile, based on publicly available information

Anna Dolnik

Charité University Medicine, Berlin, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2019 in Haematologica
Verified
Journal Article
Open access
PDF file
ETEugen Tausch
Eugen Tausch
WCWilliam Close
William Close
ADAnna Dolnik
Anna Dolnik
JBJohannes Bloehdorn
Johannes Bloehdorn
BCBrenda Chyla
Brenda Chyla
SSStephan Stilgenbauer
Stephan Stilgenbauer

1 November 2012 in Blood
Verified
Journal Article
Closed access
PDF file
ADAnna Dolnik
Anna Dolnik
JEJulia Engelmann
Julia Engelmann
MSMaren Scharfenberger-Schmeer
Maren Scharfenberger-Schmeer
JMJulian Mauch
Julian Mauch
SKSabine Kelkenberg-Schade
Sabine Kelkenberg-Schade
LBLars Bullinger
Lars Bullinger
Acute myeloid leukemia (AML) is characterized by molecular heterogeneity. As commonly altered genomic regions point to candidate genes involved in leukemogenesis, we used microarray-based comparative genomic hybridization and single nucleotide polymorphism profiling data of 391 AML cases to further narrow down genomic regions of interest. Targeted resequencing of 1000 genes located in the critical regions was performed in a representative cohort of 50 AML samples comprising all major cytogenetic subgroups. We identified 120 missense/nonsense mutations as well as 60 insertions/deletions affecting 73 different genes (∼ 3.6 tumor-specific aberrations/AML). While most of the newly identified alterations were nonrecurrent, we observed an enrichment of mutations affecting genes involved in epigenetic regulation including known candidates like TET2, TET1, DNMT3A, and DNMT1, as well as mutations in the histone methyltransferases NSD1, EZH2, and MLL3. Furthermore, we found mutations in the splicing factor SFPQ and in the nonclassic regulators of mRNA processing CTCF and RAD21. These splicing-related mutations affected 10% of AML patients in a mutually exclusive manner. In conclusion, we could identify a large number of alterations in genes involved in aberrant splicing and epigenetic regulation in genomic regions commonly altered in AML, highlighting their important role in the molecular pathogenesis of AML.

2 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCSibylle Cocciardi
Sibylle Cocciardi
ADAnna Dolnik
Anna Dolnik
SKSilke Kapp-Schwoerer
Silke Kapp-Schwoerer
FRFrank G. Rücker
Frank G. Rücker
SLSusanne Lux
Susanne Lux
KDKonstanze Döhner
Konstanze Döhner
Mutations in thenucleophosmin 1(NPM1) gene are considered founder mutations in the pathogenesis of acute myeloid leukemia (AML). To characterize the genetic composition ofNPM1mutated (NPM1mut) AML, we assess mutation status of five recurrently mutated oncogenes in 129 pairedNPM1mutsamples obtained at diagnosis and relapse. We find a substantial shift in the genetic pattern from diagnosis to relapse includingNPM1mutloss (n = 11). To better understand theseNPM1mutloss cases, we perform whole exome sequencing (WES) and RNA-Seq. At the time of relapse,NPM1mutloss patients (pts) feature distinct mutational patterns that share almost no somatic mutation with the corresponding diagnosis sample and impact different signaling pathways. In contrast, profiles of pts with persistentNPM1mutare reflected by a high overlap of mutations between diagnosis and relapse. Our findings confirm that relapse often originates from persistent leukemic clones, thoughNPM1mutloss cases suggest a second “de novo” or treatment-associated AML (tAML) as alternative cause of relapse.

1 October 2018 in Leukemia
Verified
Journal Article
Open access
PDF file
HDHartmut Döhner
Hartmut Döhner
ADAnna Dolnik
Anna Dolnik
LTLin Tang
Lin Tang
JSJohn F. Seymour
John F. Seymour
MMMark D. Minden
Mark D. Minden
HDHervé Dombret
Hervé Dombret
Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients was assessed for gene mutations. Patients received azacitidine 75 mg/m2/day x7 days (n = 240) or conventional care regimens (CCR; n = 245): intensive chemotherapy, low-dose cytarabine, or best supportive care only. Overall survival (OS) was assessed for patients with common (occurring in ≥10% of patients) cytogenetic abnormalities and karyotypes, and for patients with recurring gene mutations. There was a significant OS improvement with azacitidine vs CCR for patients with European LeukemiaNet-defined Adverse karyotype (HR 0.71 [95%CI 0.51–0.99]; P = 0.046). Azacitidine-treated patients with -5/5q-, -7/7q-, or 17p abnormalities, or with monosomal or complex karyotypes, had a 31–46% reduced risk of death vs CCR. The most frequent gene mutations were DNMT3A (27%), TET2 (25%), IDH2 (23% [R140, 15%; R172, 8%]), and TP53 (21%). Compared with wild-type, OS was significantly reduced among CCR-treated patients with TP53 or NRAS mutations and azacitidine-treated patients with FLT3 or TET2 mutations. Azacitidine may be a preferred treatment for older patients with AML with Adverse-risk cytogenetics, particularly those with chromosome 5, 7, and/or 17 abnormalities and complex or monosomal karyotypes. The influence of gene mutations in azacitidine-treated patients warrants further study.

13 September 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TET. J. Ettrich
T. J. Ettrich
DSD. Schwerdel
D. Schwerdel
ADA. Dolnik
A. Dolnik
FBF. Beuter
F. Beuter
TBT. J. Blätte
T. J. Blätte
ABA. W. Berger
A. W. Berger
Diagnosis of Cholangiocarcinoma (CCA) is difficult, thus a noninvasive approach towards (i) assessing and (ii) monitoring the tumor-specific mutational profile is desirable to improve diagnosis and tailor treatment. Tumor tissue and corresponding ctDNA samples were collected from patients with CCA prior to and during chemotherapy and were subjected to deep sequencing of 15 genes frequently mutated in CCA. A set of ctDNA samples was also submitted for 710 gene oncopanel sequencing to identify progression signatures. The blood/tissue concordance was 74% overall and 92% for intrahepatic tumors only. Variant allele frequency (VAF) in ctDNA correlated with tumor load and in the group of intrahepatic CCA with PFS. 63% of therapy naive patients had their mutational profile changed during chemotherapy. A set of 76 potential progression driver genes was identified among 710 candidates. The molecular landscape of CCA is accessible via ctDNA. This could be helpful to facilitate diagnosis and personalize and adapt therapeutic strategies.

23 May 2019 in Blood
Verified
Journal Article
Closed access
PDF file
DSDaniel Sasca
Daniel Sasca
JSJakub Szybinski
Jakub Szybinski
ASAndrea Schüler
Andrea Schüler
VSViral Shah
Viral Shah
JHJan Heidelberger
Jan Heidelberger
TKThomas Kindler
Thomas Kindler
Neural cell adhesion molecule 1 (NCAM1; CD56) is expressed in up to 20% of acute myeloid leukemia (AML) patients. NCAM1 is widely used as a marker of minimal residual disease; however, the biological function of NCAM1 in AML remains elusive. In this study we investigated the impact of NCAM1 expression on leukemogenesis, drug resistance and its role as a biomarker to guide therapy. Beside t(8;21) leukemia, NCAM1 expression was found in most molecular AML subgroups at highly heterogeneous expression levels. Using complementary genetic strategies, we demonstrated an essential role of NCAM1 in the regulation of cell survival and stress resistance. Perturbation of NCAM1 induced cell death or differentiation and sensitized leukemic blasts towards genotoxic agents in vitro and in vivo. Furthermore, Ncam1 was highly expressed in leukemic progenitor cells in a murine leukemia model, and genetic depletion of Ncam1 prolonged disease latency and significantly reduced leukemia-initiating cells upon serial transplantation. To further analyze the mechanism of the NCAM1-associated phenotype, we performed phospho-proteomics and transcriptomics in different AML cell lines. NCAM1 expression strongly associated with constitutive activation of MAPK signaling pathway, regulation of apoptosis or glycolysis. Pharmacological inhibition of MEK1/2 specifically inhibited proliferation and sensitized NCAM1-positive AML cells to chemotherapy. In summary, our data demonstrate that aberrant expression of NCAM1 is involved in the maintenance of leukemic stem cells and confers stress resistance, likely due to activation of the MAPK pathway. Targeting MEK1/2 sensitizes AML blasts to genotoxic agents indicating a role for NCAM1 as a biomarker to guide AML treatment. Key points Aberrant NCAM1 expression confers drug resistance in AML. Expression of NCAM1 activates the MAPK-ERK pathway and renders cells sensitive to MEK-inhibitors.